West Virginia University Logo

Annual Laurence and Jean DeLynn Lecture Series presents John Byrd, MD

September 4, 2019 from 4:00 PM until 5:00 PM

John C. Byrd, MD, from Ohio State University is a world renowned hematologist and distinguished professor at OSU who developed ibrutinib from lab to bedside. This is a new drug that has dramatically changed the outcome for many patients with CLL and is now finding applications in many other cancers.


Okey Patteson Auditorium, WVU Health Sciences Campus

4 p.m., reception to follow lecture in HSC Pylons lobby

John C Byrd, MD

John Byrd


College of Medicine


Internal Medicine

Academic Title


Research Program

Leukemia Research

Leadership Title

D. Warren Brown Chair of Leukemia Research
Distinguished University Professor of Medicine Medicinal Chemistry, and Veterinary Biosciences
Senior Advisor for Cancer Experimental Therapeutics

Research Interest

Leukemia, Lymphocytic, Chronic, B-Cell, Cancer, Leukemia, Myeloid, Acute, Leukemia, Lymphoma, Mantle-Cell, Lymphoma, Non-Hodgkin, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Follicular, Tumor Lysis Syndrome

Dr. Byrd’s research accomplishments relate best to studies done between the laboratory and clinic (translational work) with several different therapeutic agents active in chronic lymphocytic leukemia (CLL) and related leukemias and lymphomas. His work has shown that therapeutic agents such as rituximab, TRU-16, flavopiridol, dinaciclib and the B-cell receptor kinase inhibitors (GS1101 and ibrutinib) are effective against CLL. In particular, Dr. Byrd has been and continues to be active in developing therapeutic antibodies and other targeted agents in his pursuit of non-toxic therapies for leukemia. The basic-science and clinical work of Dr. Byrd and his colleagues played a key role in the U.S. Food and Drug Administration’s February 2014 approval for expanding the use of ibrutinib to treat certain patients with CLL.


Contact Information
Deanna Dalton

Health Sciences